Amgen to Present New Data on Repatha and Cardiovascular Portfolio at AHA 2025

Amgen to Present New Data on Repatha and Cardiovascular Portfolio at AHA 2025

By, Admin 4 November 2025

Amgen announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7–10 in New Orleans, Louisiana.

Results from the landmark VESALIUS-CV trial will be shared during the late-breaking session, “Groundbreaking Trials in Cardiometabolic Therapeutics,” on November 8. The study evaluated Repatha in patients at high cardiovascular risk but without a prior history of heart attack or stroke.
In October, Amgen reported that the trial met its dual primary endpoints, demonstrating that Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in this population — making it the first PCSK9 inhibitor to do so.

“With powerful new data that reinforce the importance of early intervention and sustained LDL-C reduction, Repatha is the first and only PCSK9 inhibitor to demonstrate an improvement over optimal lipid-lowering therapy for primary prevention,” said Dr. Jay Bradner, Executive Vice President of Research and Development at Amgen.

Amgen will also present data from the VESALIUS-REAL global observational study, which analyzed more than 1.1 million patients across 11 countries. The study assessed lipid management and MACE incidence among high-risk individuals without previous cardiovascular events, revealing that most patients did not escalate therapy despite being at elevated risk.

Additionally, results from the REPATHA-CE real-world study will be presented. This is the largest analysis of patients with established atherosclerotic cardiovascular disease (ASCVD) treated with Repatha, evaluating its effectiveness in reducing MACE over four years compared to untreated patients. The findings extend evidence from the 2017 FOURIER study to a broader and more diverse population.

Key Repatha Presentations at AHA 2025

  • VESALIUS-CV Trial: Primary results in high-risk patients without prior MI or stroke — LBS.01, Nov 8, 9:10–9:20 a.m. CST
  • VESALIUS-REAL Study: Global burden of stroke and MI in high-risk populations — Abstract #MP404, Nov 8, 2:06–2:11 p.m. CST
  • EVOLVE-MI Trial: Early use of evolocumab post-MI — Abstract #MP493, Nov 8, 1:59–2:04 p.m. CST
  • Additional abstracts include studies on very low LDL-C targets, real-world outcomes, and healthcare resource utilization.

Olpasiran and Lp(a)

Amgen will present additional findings on Olpasiran (AMG 890), a small interfering RNA (siRNA) therapy targeting lipoprotein(a) [Lp(a)]. Data from the OCEAN(a)-DOSE trial and related analyses will explore efficacy across apolipoprotein(a) isoforms and estimated coronary heart disease risk reduction.

Broader Cardiovascular Commitment

Amgen emphasized its ongoing focus on addressing interconnected cardiovascular risks such as elevated LDL-C, Lp(a), obesity, diabetes, and hypertension. The company noted that its expanding research portfolio combines clinical innovation and real-world data to advance early testing, prevention, and access to care.

Repatha has been evaluated in 51 clinical trials over 15 years involving more than 57,000 patients. It is approved in 74 countries, including the U.S., Japan, Canada, and the European Union.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!